Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA Review
08 juin 2023 08h45 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, June 08, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company) announces that it remains confident in submitting an Investigational New Drug Application...
Enochian BioSciences’ CEO Letter to Shareholders
03 avr. 2023 09h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, April 03, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- Accelerated Pre-Investigational New Drug (Pre-IND) submission to the US Food and Drug Administration (FDA) for potential cancer...
Enochian BioSciences Announces a Scientific Presentation of Proof-of-Concept Studies for a Potential Therapy for Cancers with a Poor Life Expectancy by a Leading Researcher
29 mars 2023 09h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, March 29, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the “Company”) announces that Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy...
Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements
13 mars 2023 08h30 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, March 13, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company) announced that it has achieved full compliance with NASDAQ filing requirements. The Annual...
Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended December 31, 2022
23 févr. 2023 16h04 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, Feb. 23, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- On February 16, 2023, Enochian BioSciences Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC...
Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended September 30, 2022
30 nov. 2022 17h20 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, Nov. 30, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- On November 23, 2022, Enochian BioSciences Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC...
Enochian BioSciences Forges Ahead With Focused Approach, Promising Future
24 oct. 2022 08h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, Oct. 24, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)—Enochian BioSciences (the Company) recently announced significant progress toward re-prioritizing its focus on curing some of the...
Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Annual Report on Form 10-K
21 oct. 2022 17h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, Oct. 21, 2022 (GLOBE NEWSWIRE) -- On October 17, 2022, Enochian BioSciences, Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating...
Enochian BioSciences Awarded U.S. Patent For Its Promising Oncology Platform
17 oct. 2022 08h30 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Today, Enochian BioSciences (the Company) announced that it was awarded a U.S. patent for its proprietary cancer treatment platform that could...
Enochian BioSciences Appoints Dr. Richard Whitley As Senior Scientific Advisor
25 juil. 2022 10h15 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, July 25, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)—Today, Enochian BioSciences (the Company) announced that Dr. Richard (Rich) Whitley, M.D., of the University of Alabama at Birmingham...